Trial Profile
Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients With Advanced Solid Tumors and Recurrent High-Grade Gliomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 May 2023
Price :
$35
*
At a glance
- Drugs Saposin C (Primary)
- Indications Colorectal cancer; Ependymoma; Gastrointestinal cancer; Gastrointestinal stromal tumours; Glioblastoma; Glioma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Bexion Pharmaceuticals
- 19 Apr 2023 Results assessing whether BXQ-350 alleviated CIPN symptoms in several patients soon after receiving BXQ-350, presented at the 114th Annual Meeting of the American Association for Cancer Research
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium